
Funding opportunities for partnerships with industry

Elaine Evans, Senior Innovation Lead Healthcare & Medicines
6 March 2018

Funding opportunities for partnerships with industry

- Innovate UK, the ISCF and the Grand Challenges
- Funding opportunities and opportunities for collaboration
- Access to other infrastructure

Innovate UK

The UK's innovation agency

Innovate UK drives **productivity and growth** by supporting businesses to realise the potential of new technologies, develop ideas and **make them a commercial success**

To **stay competitive as an advanced economy**, we need to do things that others cannot do, or to do things in different and better ways.

Delivered by

Innovate UK



Investment of
£2.2bn
since 2007



industry match
funding taking
the total value
of projects above

£3.75bn



Up to
£16bn
in added value
to the economy



up to
£7.30
for every **£1**
we've invested.

We've funded around
11,000
projects



8,000
unique
organisations
involved



8 jobs for each
organisation
involved

70,000
jobs created in total





Industrial Strategy Challenge Fund

- Industry-led and powered by multi-disciplinary research and business academic collaboration
- Develop UK industries for the future, driving progress in technologies where the UK can become a world-leader in both research and commercialisation

Delivered by

Innovate UK



Industrial Strategy Challenge Fund



Medicines manufacturing technologies



Batteries for clean and flexible energy storage



Manufacturing and materials of the future

Deliv

Innovate UK



Satellites and space technology





£197m
over 4 years

**Medicines
manufacturing
technologies**

Developing first-of-a-kind technologies for the manufacture of medicines that will speed up patient access to new drugs and treatments,

Industrial Strategy Grand Challenges

Building our
#IndustrialStrategy



AI and Data
Economy



Healthy
ageing



Clean
growth



Future of
mobility

Delivered by

Innovate UK



Health & Life Science Competitions

Delivered by

Innovate UK



Open Competitions	Amount	Deadline
Support for SME's to evaluate innovative Medical Technologies (OLS)	£1m	21 st March '18
Health & Life Sciences/ Emerging and Enabling Technologies Sector Competition	£19m	28 th March '18
Asthma UK/Innovate UK	£1.25m	27 th March '18
Digital Health Catalyst Round 2 2018	£8m	18 th April '18
NHS Test Beds	£6m	27 th March '18

Delivered by

Innovate UK



Further details including eligibility, scope, application details and other visit the **Innovation Funding Service**

Planned Competitions	Planned Opening
Open Competition	1 March
UK-China AMR	Planned start Feb'18 China: ~April'18
ISCF Medicine Manufacturing R2	12 th March'18
Biomedical Catalyst R2 2018	26 th March'18
Precision Medicine Investment Accelerator	30 th April'18
SBRI Pre-Clinical Vaccines Phase 2	25 th June'18

Delivered by

Innovate UK





“Affinity can reduce chemotherapy cancellations and free up chemotherapy appointments”

Susana, Consultant Medical Oncologist, Royal Marsden NHS Trust

affinity™

Personalising cancer therapy through home blood count monitoring



One drop of blood



Red blood cell counts



White blood cell counts



Platelet counts

- a 20% reduction in hospital appointments,
- faster delivery of treatment for life-threatening conditions,
- personalised use of prophylactic medication, and
- earlier interventions to help correct adverse events.

Affinity was made possible through Innovate UK support that enabled Entia to secure partnerships with a wide range of leading academic and clinical collaborators.





8 Dec 2017 - Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

“Autifony has pioneered the development of Kv3.1/3.2 modulators for the treatment of schizophrenia. We welcome the opportunity to collaborate with Boehringer Ingelheim. We are also grateful for the support from Innovate UK’s **Biomedical Catalyst**, which has enabled a highly successful collaboration between Autifony, the **Universities of Manchester and Newcastle**, and the **Institute of Psychiatry, Psychology and Neuroscience at Kings College London.**”

€25m upfront fee; further payments up to €17.5m on achievement of short term milestones. Total potential transaction up to €627.5m once Boehringer Ingelheim has exercised its option.


Assessa[®]

Clinical decision support for patient selection and post-marketing surveillance

We partner with biopharma companies to improve clinical trial patient selection and provide clinical decision support services to improve the safety and efficacy of their therapeutics.


Assessa is a secure online digital platform to enable the remote transfer of clinical and imaging data to provide central expert and automated review and analysis. Referring clinicians then receive actionable information to inform treatment decisions at the point-of-care.

Ixico led a Biomedical Catalyst collaborative project in 2013 with Imperial College London and Cambridge Cognition



Catapults: where they are

Our network of Catapult centres is located throughout the UK in areas of strategic importance to each sector.



“To innovate, we need open centres where academia and business can get together and drive forward great ideas into manufactured products. And that’s what the Catapults are delivering for us.”

Juergen Maier, Chief Executive,
Siemens UK

Regional Centres

Digital	Satellite Applications	
North East and Tees Valley	North East	East Midlands
Yorkshire	Scotland	South Coast
Brighton	South West	
Northern Ireland		

We can't stop
thinking about
the future

Delivered by

Innovate UK

